ArticleCureus2026
Frailty in Cardiorenal Care: A Geriatric Perspective on the 2026 European Society of Cardiology Guidelines.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2026 European Society of Cardiology Guidelines for the Management of Cardiovascular Disease and Chronic Kidney Disease provide an integrated framework for cardiorenal risk detection, treatment modification, and health service planning. However, chronological age, kidney function, albuminuria, and conventional cardiovascular risk measures cannot fully capture the clinical heterogeneity of older adults. Frailty, sarcopenia, cognitive impairment, multimorbidity, polypharmacy, and limited life expectancy may substantially alter both the expected benefits and burdens of treatment. Conversely, advanced age alone should not justify withholding evidence-based cardiorenal therapy from functionally preserved older adults. This editorial proposes STAMP-F as a conceptual and currently unvalidated extension of the guideline framework. The additional component represents Frailty, Function, and Future Healthspan and is intended to support individualized decisions rather than serve as an official recommendation, diagnostic criterion, or prognostic instrument. Brief measures such as the Clinical Frailty Scale and gait speed may provide pragmatic entry points for this assessment. Incorporating these domains may help align organ-protective treatment with outcomes that matter to older adults, including mobility, cognition, independence, quality of life, and healthspan. Prospective studies are needed to determine whether this approach improves clinical decision-making and patient-centered outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.